Janus Living | 10-K: FY2025 Revenue: USD 24.84 M

Revenue: As of FY2025, the actual value is USD 24.84 M.EPS: As of FY2025, the actual value is USD -5.91.EBIT: As of FY2025, the actual value is USD -18.98 M.Overall Company Performance (Continuing Operations)RevenueFiscal Year Ended December 27, 2025: $24,840 thousandFiscal Year Ended December 28, 2024: $11,887 thousandCost of RevenueFiscal Year Ended December 27, 2025: $14,652 thousandFiscal Year Ended December 28, 2024: $6,238 thousandGross ProfitFiscal Year Ended December 27, 2025: $10,188 thousandFiscal Year Ended December 28, 2024: $5,649 thousandSelling, General and Administrative ExpensesFiscal Year Ended December 27, 2025: $33,039 thousandFiscal Year Ended December 28, 2024: $12,572 thousandOperating LossFiscal Year Ended December 27, 2025: -$22,851 thousandFiscal Year Ended December 28, 2024: -$6,923 thousandInterest Expense, NetFiscal Year Ended December 27, 2025: -$3,869 thousandFiscal Year Ended December 28, 2024: -$1,159 thousandRealized Gain on Exchange TransactionsFiscal Year Ended December 27, 2025: $374 thousandFiscal Year Ended December 28, 2024: $1,019 thousandUnrealized Loss on Marketable SecuritiesFiscal Year Ended December 27, 2025: -$0 thousandFiscal Year Ended December 28, 2024: -$1,238 thousandUnrealized Loss on Cryptocurrency AssetsFiscal Year Ended December 27, 2025: -$402,054 thousandFiscal Year Ended December 28, 2024: -$0 thousandUnrealized Gain on Exchange TransactionsFiscal Year Ended December 27, 2025: $768 thousandFiscal Year Ended December 28, 2024: $0 thousandOther Expense, NetFiscal Year Ended December 27, 2025: -$596 thousandFiscal Year Ended December 28, 2024: -$160 thousandNet Loss from Continuing OperationsFiscal Year Ended December 27, 2025: -$341,486 thousandFiscal Year Ended December 28, 2024: -$8,301 thousandDiscontinued Operations (Biotechnology Segment)Loss from Discontinued OperationsFiscal Year Ended December 27, 2025: -$3,898 thousandFiscal Year Ended December 28, 2024: -$2,148 thousandIncome Tax Benefit from Discontinued OperationsFiscal Year Ended December 27, 2025: -$877 thousandFiscal Year Ended December 28, 2024: -$2,881 thousandNet (Loss) Income from Discontinued OperationsFiscal Year Ended December 27, 2025: -$3,021 thousandFiscal Year Ended December 28, 2024: $733 thousandTotal Company PerformanceNet LossFiscal Year Ended December 27, 2025: -$344,507 thousandFiscal Year Ended December 28, 2024: -$7,568 thousandAdjusted EBITDA (Non-GAAP)Total Fiscal Year Ended December 27, 2025: -$15,429 thousandTotal Fiscal Year Ended December 28, 2024: -$1,509 thousandFintech Segment (2025): -$2,611 thousandBiotech (Discontinued Operations) Segment (2025): -$1,969 thousandCorporate and Other Segment (2025): -$10,849 thousandSegment PerformanceFintech SegmentRevenue (2025): $24,840 thousandCost of Revenue (2025): $14,652 thousandGross Profit (2025): $10,188 thousandGross Margin Percentage (2025): 41.0%Operating Loss (2025): -$6,182 thousandRevenue (2024): $11,887 thousandCost of Revenue (2024): $6,238 thousandGross Profit (2024): $5,649 thousandGross Margin Percentage (2024): 48.0%Operating Income (2024): $193 thousandRevenue increased by approximately $13.0 million in 2025 compared to 2024, primarily due to the acquisitions of ALT5 Subsidiary in May 2024 and Mswipe in May 2025.Gross profit increased by approximately $4.6 million in 2025 compared to 2024, also due to the acquisitions.Selling, general and administrative expenses for continuing operations increased by approximately $20.5 million in 2025 compared to 2024, mainly due to acquisitions, higher bad debt, legal expenses, and increased stock-based compensation.Biotechnology Segment (Discontinued Operations)Operating Loss (2025): -$3,898 thousandOperating Loss (2024): -$2,148 thousandSelling, general and administrative expenses increased over the prior year due to increases in professional fees and research and development costs.Corporate and Other SegmentRevenue (2025 & 2024): $0 thousandOperating Loss (2025): -$16,669 thousandOperating Loss (2024): -$7,116 thousandSelling, general and administrative expenses increased by approximately $9.6 million, primarily due to increased costs for stock-based compensation and legal expenses, as well as other professional services.Cash FlowOperating ActivitiesFiscal Year Ended December 27, 2025: -$7,157 thousand (cash used)Fiscal Year Ended December 28, 2024: $1,777 thousand (cash provided)The decrease in cash from operations in 2025 was primarily due to the results of operations.Investing ActivitiesFiscal Year Ended December 27, 2025: -$706,606 thousand (cash used)Fiscal Year Ended December 28, 2024: $5,853 thousand (cash provided)Cash used in investing activities in 2025 was primarily for the purchase of WLFI tokens, partially offset by tokens redeemed.Financing ActivitiesFiscal Year Ended December 27, 2025: $716,797 thousand (cash provided)Fiscal Year Ended December 28, 2024: $6,093 thousand (cash provided)Cash provided by financing activities in 2025 primarily relates to proceeds from equity financing and issuance of notes payable, partially offset by fees for equity financing and payments on notes payable.Other Key Financial MetricsCash and Cash EquivalentsAs of December 27, 2025: $6,222 thousandAs of December 28, 2024: $7,177 thousandApproximately $3.5 million of cash is fully reserved in connection with a legal matter as of December 27, 2025.Working CapitalAs of December 27, 2025: -$21,900 thousand (net negative working capital), with total current assets of $29,466 thousand and total current liabilities of $51,399 thousand.Cryptocurrency Assets (WLFI tokens)Fair Value as of December 27, 2025: $1,054,663 thousandUnits Held as of December 27, 2025: 7,283,585,650 WLFI tokensCost Basis as of December 27, 2025: $1,456,717,130 thousandAn unrealized loss of approximately -$402.1 million was recognized in 2025 related to the change in fair value of WLFI tokens.Outlook / GuidanceJanus Living, Inc. plans to use proceeds from a $15.0 million draw-down to fund a share repurchase program, acquire additional WLFI tokens, and for general corporate purposes. The company intends to raise additional funds for its Biotechnology segment’s Phase IIb clinical trials and other strategic investments, with a potential plan to decouple the Biotechnology segment into a stand-alone entity while retaining a controlling interest. Management views its approximately 7.3 billion WLFI tokens, valued at $1.05 billion as of December 27, 2025, as a significant financial resource for liquidity, subject to market price risk, with a policy allowing sales for liquidity needs or material portfolio rebalancing events.